Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» polatuzumab vedotin
polatuzumab vedotin
As generic competition stutter sales of top oncology drugs, Roche secures speedy review for pair of experimental cancer offerings
Endpoints
Tue, 02/19/19 - 12:15 pm
Roche
Seattle Genetics
generics
antibody-drug conjugate
polatuzumab vedotin
relapsed or refractory diffuse large B-cell lymphoma
entrectinib
solid tumors